Xbrane Biopharma
0,18
SEK
-0,11 %
XBRANE
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Mindre end 1K følgere
-0,11%
+1,69%
+11,94%
-19,1%
+6,01%
+4,18%
-98,26%
-96,82%
-95,28%
Xbrane Biopharma is a biotechnology company. The company specializes in research and development of drugs for the treatment of critical illnesses. Today, the business is focused on research in microspherical technology and in the development of protein molecules. The products are used in the treatment of prostate cancer and endometriosis, as well as in rare and serious eye diseases. The company's head office is located in Solna.
Læs mereMarkedsværdi
275,79 mio. SEK
Aktieomsætning
363,89 t SEK
Omsætning
238,73 mio.
EBIT %
-134,95 %
P/E
-
Udbytteafkast, %
-
Finanskalender
21.2
2025
Årsrapport '24
5.5
2025
Generalforsamling '25
8.5
2025
Delårsrapport Q1'25
ViserAlle indholdstyper
The number of shares and votes in Xbrane has changed as a result of 2,706,898 shares being issued during January through the exercise of warrants in December 2024.
Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools